Details for Patent: 11,400,077
✉ Email this page to a colleague
Which drugs does patent 11,400,077 protect, and when does it expire?
Patent 11,400,077 protects RYZUMVI and is included in one NDA.
This patent has thirteen patent family members in thirteen countries.
Drugs Protected by US Patent 11,400,077
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF PHARMACOLOGICALLY-INDUCED MYDRIASIS | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,400,077
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019366451 | ⤷ Subscribe | |||
| Brazil | 112021007725 | ⤷ Subscribe | |||
| Canada | 3116589 | ⤷ Subscribe | |||
| China | 113164452 | ⤷ Subscribe | |||
| European Patent Office | 3870170 | ⤷ Subscribe | |||
| Israel | 282624 | ⤷ Subscribe | |||
| Japan | 2022505950 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
